Otsuka (4768.T) Stock Price
Otsuka Price
Revenue has compounded at 6.0% per year over the past 19 years to 1.32 T JPY. Earnings per share have grown at 3.9% per year over the last 19 years. Otsuka's net margin stands at 4.9%, broadly stable from 4.7% several years earlier. Otsuka currently offers a dividend yield of about 2.22%. The payout ratio is around 53% of earnings. The dividend has grown at 27.9% per year over the past 19 years. Analysts set a median price target of 3,876.00 JPY, implying 4.6% below the current price. Of 18 analysts, 12 rate the stock a buy — an overall Buy consensus.
Otsuka stock price
Otsuka business model & stock analysis
Frequently asked questions about Otsuka
The business model of Otsuka Corp revolves around healthcare and consumer products. As a multinational company, Otsuka Corp focuses on developing innovative pharmaceuticals and nutraceuticals, along with providing related healthcare services. They aim to improve the quality of life by addressing various medical needs and delivering reliable solutions. Otsuka Corp is committed to research and development, manufacturing, and marketing of products that cater to mental health, oncology, gastroenterology, and nephrology, among other therapeutic areas. Through their diverse portfolio and strategic partnerships, Otsuka Corp aims to contribute to the well-being of individuals worldwide.
Otsuka Corp is primarily active in the pharmaceutical and healthcare industries.
The main competitors of Otsuka Corp in the market are multinational pharmaceutical companies such as Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., and Eisai Co., Ltd. These rivals operate in similar sectors and offer a wide range of healthcare products and services. Otsuka Corp competes with these companies in terms of research and development, product innovation, market presence, and global reach. Despite the fierce competition, Otsuka Corp has established itself as a renowned player in the industry, focusing on areas like pharmaceuticals, nutraceuticals, and medical devices.
Otsuka Corp, a renowned Japanese company, has a rich history and background. Established in 1964, Otsuka Corp has been dedicated to enhancing the health and well-being of people through its diverse range of products and services. The company focuses on pharmaceuticals, nutraceuticals, and consumer products, all aimed at meeting the evolving needs of individuals worldwide. Otsuka Corp's commitment to innovation and breakthrough technologies has led to the development of groundbreaking treatments in areas such as mental health, oncology, and nephrology. With its extensive global presence, Otsuka Corp strives to make a positive impact on society by improving healthcare and contributing to the betterment of people's lives.
Otsuka Corp has achieved several significant milestones throughout its history. One noteworthy achievement is the introduction of its flagship product, Pocari Sweat, a popular electrolyte drink that has gained widespread recognition and success in the market. Additionally, the company has successfully expanded its global presence with various subsidiaries and strategic collaborations, enabling it to penetrate international markets more effectively. Otsuka Corp has also made significant advancements in the pharmaceutical industry, particularly in mental health research and development. Notably, the company introduced Abilify, a widely used medication for treating schizophrenia and bipolar disorder. The continuous dedication to innovation and strategic growth has established Otsuka Corp as a leading player in the global market.
Otsuka Corp is primarily present in Japan, where it is headquartered. The company has a strong presence in many other countries and regions as well, including the United States, China, Europe, and Southeast Asia. With its global reach and diverse operations, Otsuka Corp continues to expand its footprint and deliver its innovative products and services to customers around the world.
Otsuka Corp represents a strong set of values and a unique corporate philosophy. The company is committed to creating innovative products and services that contribute to the well-being of people worldwide. With a focus on the three values of integrity, perseverance, and entrepreneurship, Otsuka Corp strives to make a positive impact within society. By combining their expertise in various fields, the company aims to tackle global healthcare challenges and fulfill their corporate mission of improving the health and happiness of people globally. Otsuka Corp's dedication to continuous innovation and social responsibility showcases their commitment to creating a better future for all.
Analysts currently set an average price target of 3,816.37 JPY for the Otsuka stock (median: 3,876.00 JPY), implying -6.0 % versus the latest price. The consensus is based on 18 analyst ratings.
18 analysts currently rate the Otsuka stock: 12 recommend buying, 3 holding and 3 selling. For 2026, analysts expect Otsuka to generate revenue of 1.41 T JPY and earnings per share of 178.34 JPY.
Converted at the current exchange rate, the Otsuka share trades at 22.92 EUR (4,061.00 JPY).
The Otsuka share (4768.T) is listed on 3 stock exchanges, including: Tokio (JPX) (4768.T), Frankfurt (OTK.F).
Otsuka Corp is a Japanese company that operates in various business fields. The company specializes in pharmaceuticals, nutrition, cosmetics, and beverages and operates worldwide. It is considered a global player in the industry with approximately 47,000 employees. In the pharmaceutical sector, Otsuka develops and produces innovative medications for various diseases such as neurology, oncology, cardiology, and psychiatry. Some examples include Abilify, an antipsychotic medication for schizophrenia and bipolar disorders, and Rexulti, a medication for the treatment of depression and schizophrenia. Another well-known product is the gastrointestinal medication Pletal, used for impaired blood flow. In the nutrition sector, Otsuka offers dietary supplements suitable for athletes and general use. This includes products like Pocari Sweat, a beverage containing electrolytes to prevent fluid loss during physical activity. Another product is Calorie Mate, a meal replacement supplement. Additionally, Otsuka is active in the cosmetics industry and offers numerous skincare products. Some of the notable products include the Oronine H Ointment line, which aims to help with skin conditions, injuries, and burns, and the Skin Aqua line, which serves as sun protection products. In the beverage sector, Otsuka offers natural juices and teas distributed in Japan and other countries. Otsuka Corp emphasizes intensive research and development in the development of its products. To achieve this goal, the company collaborates with renowned universities and research institutions worldwide. To ensure the quality of its products, Otsuka adheres to strict quality standards that ensure responsible practices with regard to human beings and the environment. As a globally oriented company, Otsuka is continually striving to adapt its products and services to meet the needs of its customers. To achieve this, the company works closely with local partners and experts. Overall, Otsuka's business model is characterized by intensive research and development, high-quality standards, and a wide range of products in different business sectors. The company specializes in developing innovative products that provide high value to customers. Responsible corporate governance is a key focus.
The expected revenue of Otsuka is 1.41 T JPY. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Otsuka is 67.82 B JPY. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Otsuka is currently 22.77. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Otsuka stock.
The price-to-sales ratio (P/S) of Otsuka is currently 1.10. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Otsuka stock.
The Eulerpool Quality Score for Otsuka is 7/10.
The ISIN of Otsuka is JP3188200004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Otsuka is 502503. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Otsuka is 4768.T. The ticker symbol is used to trade Otsuka shares on the stock exchange.
Otsuka stock
Otsuka Peer Group
Otsuka Ticker
Otsuka FIGI
All fundamentals and in-depth analysis of Otsuka
Our stock analysis for Otsuka stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Otsuka. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.